ArticlePakistan journal of medical sciences2014
Systemic lupus erythematosis with severe aplastic anemia successfully treated with rituximab and antithymocyte globulin.
Article in Pakistan journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Case Report: Rare aplastic anemia in pediatric systemic lupus erythematosus: a case series and systematic literature review.Frontiers in pediatrics · 2025Article
- Pancytopenia with aplastic anemia in systemic lupus erythematosus: case series and literature review.Rheumatology international · 2024Review
- Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature.Seminars in arthritis and rheumatism · 2018Review
- Outcomes of rituximab therapy in refractory lupus: A meta-analysis.European journal of rheumatology · 2018Article
- Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia.Bone marrow transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematologic disorders are very common in Systmic lupus erythematosus (SLE).First presentation of SLE with severe aplastic anemia (SAA) is extremely rare. We report a patient with the diagnosis of secondary SAA associated with SLE. Conventional therapy was not effective. She received Rituximab (RTX) and Antithymocyte globulin (ATG) therapy, her response was satisfactory finally. Her hematologic parameters were within normal ranges until last follow-up, eight months and six months after therapy was initiated with RTX and ATG, respectively. This is the first time RTX and ATG were successfully used in the treatment of SAA secondary to SLE.
Indexed as
Identifiers
24772161PMC3999028W2114899955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.